Q-omics provides the consensus-scored MYOM3 profile across patient tissues and cancer cell-line models. MYOM3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MYOM3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, MYOM3 RNA expression shows 13,351 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and COAD as cancer lineages where MYOM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYOM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYOM3 survival associations across molecular data types. MYOM3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (12) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYOM3 RNA expression–survival associations across cancer types. High MYOM3 expression shows unfavorable associations in MESO, UVM, LGG and LUAD, but favorable associations in KIRP and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MYOM3 RNA expression.
This table summarizes MYOM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYOM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYOM3 shows lower tumor expression in KICH, BRCA and UCEC and higher tumor expression in COAD, LIHC and STAD. The COAD box plot shows higher MYOM3 RNA expression in tumor versus normal tissue (log2 FC = +1.502, t-test p < 0.001).
This table shows molecular features associated with MYOM3 in patient tissues and cancer cell lines. In patient samples, MYOM3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MYOM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Myeloma.
